放射免疫療法の世界市場：市場シェアおよびランキング・全体の売上および需要予測 (2024-2030年)

世界の放射免疫療法の市場規模は、2023年の18億6,500万米ドルから、予測期間中は14.63％のCAGRで推移し、2030年には54億800万米ドルの規模に成長すると予測されています。

北米市場は2023年の11億米ドルから、同期間中は14.13％のCAGRで推移し、2030年には32億7,400万米ドルに達すると予測されています。アジア太平洋市場は2023年の1億7,172万米ドルから、18.84％のCAGRで推移し、2030年には5億3,470万米ドルに達すると予測されています。欧州市場は2023年の5億7,441万米ドルから、14.48％のCAGRで推移し、2030年には15億8,123万米ドルに達すると予測されています。

当レポートでは、世界の放射免疫療法の市場を調査し、市場および製品の概要、市場成長への各種影響因子の分析、市場規模の推移・予測、タイプ別・用途別、地域・主要国別の詳細分析、競合環境、市場シェア、ランキング、主要企業のプロファイルなどをまとめています。

目次

第1章 市場概要

• 放射免疫療法：製品概要
• 世界市場の規模・予測
• 市場動向・促進要因
  • 産業動向
  • 市場促進要因・機会
  • 市場課題
  • 市場抑制要因
• 前提と制限
• 調査目的
• 調査年数

第2章 競合分析：企業別

• 主要企業の収益ランキング
• 収益：企業別
• 主要企業の営業エリア・本社
• 主要企業の提供製品
• 主要企業の参入日
• 競合分析
• M&A、拡大

第3章 タイプ別セグメント

• タイプ別概要
  • ベータ線放出
  • 標的アルファ線療法
• 販売額
  • 販売額：2019 vs 2023 vs 2030
  • 販売額の推移・予測
  • 販売額の推移・予測 (%)

第4章 用途別セグメント

• 用途別概要
  • 固形腫瘍
  • 非ホジキンリンパ腫
• 販売額
  • 販売額：2019 vs 2023 vs 2030
  • 販売額の推移・予測
  • 販売額の推移・予測 (%)

第5章 地域別セグメント

• 販売額
  • 販売額：2019 vs 2023 vs 2030
  • 販売額の推移
  • 販売額の予測
  • 販売額の推移・予測 (%)
• 北米
• 欧州
• アジア太平洋
• 南米
• 中東・アフリカ

第6章 主要国/地域別セグメント

• 主要国/地域別の成長動向：2019 vs 2023 vs 2030
• 主要国・地域別の販売額
• 北米
• 欧州
• 中国
• アジア太平洋
• 南米
• 中東・アフリカ

第7章 企業プロファイル

• Bayer
• Novartis
• Lantheus
• Aurobindo Pharma
• Mundipharma
• China Isotope &Radiation
• Curium Pharmaceuticals
• Gilead Sciences
• Clarity Pharmaceuticals
• Curasight
• Nordic Nanovector
• Philogen
• RadioMedix
• Telix Pharmaceuticals
• Orano Med
• Actinium Pharmaceuticals
• Y-mAbs Therapeutics
• Fusion Pharmaceuticals

第8章 産業チェーン分析

• 産業チェーン
• 上流分析
• 中流分析
• 下流分析（顧客分析）
• 販売モデルと販売チャネル

第9章 調査結果・総論

第10章 付録

List of Tables

• Table 1. Radioimmunotherapy Market Trends
• Table 2. Radioimmunotherapy Market Drivers & Opportunity
• Table 3. Radioimmunotherapy Market Challenges
• Table 4. Radioimmunotherapy Market Restraints
• Table 5. Global Radioimmunotherapy Revenue by Company (2019-2024) & (US$ Million)
• Table 6. Global Radioimmunotherapy Revenue Market Share by Company (2019-2024)
• Table 7. Key Companies Radioimmunotherapy Area Served and Headquarters
• Table 8. Key Companies Radioimmunotherapy Product Type
• Table 9. Key Companies Time to Begin Mass Production of Radioimmunotherapy
• Table 10. Global Radioimmunotherapy Companies Market Concentration Ratio (CR5 and HHI)
• Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioimmunotherapy as of 2023)
• Table 12. Mergers & Acquisitions, Expansion Plans
• Table 13. Key Players of Ibritumomab
• Table 14. Key Players of Apamistamab
• Table 15. Key Players of Lilotomab
• Table 16. Key Players of Omburtamab
• Table 17. Global Radioimmunotherapy Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
• Table 18. Global Radioimmunotherapy Sales Value by Type (2019-2024) & (US$ Million)
• Table 19. Global Radioimmunotherapy Sales Value by Type (2025-2030) & (US$ Million)
• Table 20. Global Radioimmunotherapy Sales Market Share in Value by Type (2019-2024)
• Table 21. Global Radioimmunotherapy Sales Market Share in Value by Type (2025-2030)
• Table 22. Global Radioimmunotherapy Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
• Table 23. Global Radioimmunotherapy Sales Value by Application (2019-2024) & (US$ Million)
• Table 24. Global Radioimmunotherapy Sales Value by Application (2025-2030) & (US$ Million)
• Table 25. Global Radioimmunotherapy Sales Market Share in Value by Application (2019-2024)
• Table 26. Global Radioimmunotherapy Sales Market Share in Value by Application (2025-2030)
• Table 27. Global Radioimmunotherapy Sales Value by Region, (2019 VS 2023 VS 2030) & (US$ Million)
• Table 28. Global Radioimmunotherapy Sales Value by Region (2019-2024) & (US$ Million)
• Table 29. Global Radioimmunotherapy Sales Value by Region (2025-2030) & (US$ Million)
• Table 30. Global Radioimmunotherapy Sales Value by Region (2019-2024) & (%)
• Table 31. Global Radioimmunotherapy Sales Value by Region (2025-2030) & (%)
• Table 32. Key Countries/Regions Radioimmunotherapy Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
• Table 33. Key Countries/Regions Radioimmunotherapy Sales Value, (2019-2024) & (US$ Million)
• Table 34. Key Countries/Regions Radioimmunotherapy Sales Value, (2025-2030) & (US$ Million)
• Table 35. Bayer Company Details
• Table 36. Bayer Business Overview
• Table 37. Bayer Radioimmunotherapy Products and Services
• Table 38. Bayer Revenue in Radioimmunotherapy Business (2019-2024) & (US$ Million)
• Table 39. Bayer Radioimmunotherapy SWOT Analysis
• Table 40. Bayer Business Strategy
• Table 41. Novartis Company Details
• Table 42. Novartis Business Overview
• Table 43. Novartis Radioimmunotherapy Products and Services
• Table 44. Novartis Revenue in Radioimmunotherapy Business (2019-2024) & (US$ Million)
• Table 45. Novartis Radioimmunotherapy SWOT Analysis
• Table 46. Novartis Business Strategy
• Table 47. Lantheus Company Details
• Table 48. Lantheus Business Overview
• Table 49. Lantheus Radioimmunotherapy Products and Services
• Table 50. Lantheus Revenue in Radioimmunotherapy Business (2019-2024) & (US$ Million)
• Table 51. Lantheus Radioimmunotherapy SWOT Analysis
• Table 52. Lantheus Business Strategy
• Table 53. Aurobindo Pharma Company Details
• Table 54. Aurobindo Pharma Business Overview
• Table 55. Aurobindo Pharma Radioimmunotherapy Products and Services
• Table 56. Aurobindo Pharma Revenue in Radioimmunotherapy Business (2019-2024) & (US$ Million)
• Table 57. Aurobindo Pharma Radioimmunotherapy SWOT Analysis
• Table 58. Aurobindo Pharma Business Strategy
• Table 59. Mundipharma Company Details
• Table 60. Mundipharma Business Overview
• Table 61. Mundipharma Radioimmunotherapy Products and Services
• Table 62. Mundipharma Revenue in Radioimmunotherapy Business (2019-2024) & (US$ Million)
• Table 63. Mundipharma Business Strategy
• Table 64. China Isotope & Radiation Company Details
• Table 65. China Isotope & Radiation Business Overview
• Table 66. China Isotope & Radiation Radioimmunotherapy Products and Services
• Table 67. China Isotope & Radiation Revenue in Radioimmunotherapy Business (2019-2024) & (US$ Million)
• Table 68. China Isotope & Radiation Radioimmunotherapy SWOT Analysis
• Table 69. China Isotope & Radiation Business Strategy
• Table 70. Curium Pharmaceuticals Company Details
• Table 71. Curium Pharmaceuticals Business Overview
• Table 72. Curium Pharmaceuticals Radioimmunotherapy Products and Services
• Table 73. Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2019-2024) & (US$ Million)
• Table 74. Curium Pharmaceuticals Radioimmunotherapy SWOT Analysis
• Table 75. Curium Pharmaceuticals Business Strategy
• Table 76. Gilead Sciences Company Details
• Table 77. Gilead Sciences Business Overview
• Table 78. Gilead Sciences Radioimmunotherapy Products and Services
• Table 79. Gilead Sciences Business Strategy
• Table 80. Clarity Pharmaceuticals Company Details
• Table 81. Clarity Pharmaceuticals Business Overview
• Table 82. Clarity Pharmaceuticals Radioimmunotherapy Products and Services
• Table 83. Clarity Pharmaceuticals Radioimmunotherapy SWOT Analysis
• Table 84. Clarity Pharmaceuticals Business Strategy
• Table 85. Curasight Company Details
• Table 86. Curasight Business Overview
• Table 87. Curasight Radioimmunotherapy Products and Services
• Table 88. Curasight Radioimmunotherapy SWOT Analysis
• Table 89. Curasight Business Strategy
• Table 90. Nordic Nanovector Company Details
• Table 91. Nordic Nanovector Business Overview
• Table 92. Nordic Nanovector Radioimmunotherapy Products and Services
• Table 93. Nordic Nanovector Radioimmunotherapy SWOT Analysis
• Table 94. Nordic Nanovector Business Strategy
• Table 95. Philogen Company Details
• Table 96. Philogen Business Overview
• Table 97. Philogen Radioimmunotherapy Products and Services
• Table 98. Philogen Radioimmunotherapy SWOT Analysis
• Table 99. Philogen Business Strategy
• Table 100. RadioMedix Company Details
• Table 101. RadioMedix Business Overview
• Table 102. RadioMedix Radioimmunotherapy Products and Services
• Table 103. RadioMedix Business Strategy
• Table 104. Telix Pharmaceuticals Company Details
• Table 105. Telix Pharmaceuticals Business Overview
• Table 106. Telix Pharmaceuticals Radioimmunotherapy Products and Services
• Table 107. Telix Pharmaceuticals Radioimmunotherapy SWOT Analysis
• Table 108. Telix Pharmaceuticals Business Strategy
• Table 109. Orano Med Company Details
• Table 110. Orano Med Business Overview
• Table 111. Orano Med Radioimmunotherapy Products and Services
• Table 112. Orano Med Radioimmunotherapy SWOT Analysis
• Table 113. Orano Med Business Strategy
• Table 114. Actinium Pharmaceuticals Company Details
• Table 115. Actinium Pharmaceuticals Business Overview
• Table 116. Actinium Pharmaceuticals Radioimmunotherapy Products and Services
• Table 117. Actinium Pharmaceuticals Radioimmunotherapy SWOT Analysis
• Table 118. Actinium Pharmaceuticals Business Strategy
• Table 119. Y-mAbs Therapeutics Company Details
• Table 120. Y-mAbs Therapeutics Business Overview
• Table 121. Y-mAbs Therapeutics Radioimmunotherapy Products and Services
• Table 122. Y-mAbs Therapeutics Business Strategy
• Table 123. Fusion Pharmaceuticals Company Details
• Table 124. Fusion Pharmaceuticals Business Overview
• Table 125. Fusion Pharmaceuticals Radioimmunotherapy Products and Services
• Table 126. Fusion Pharmaceuticals Business Strategy
• Table 127. Key Raw Materials Lists
• Table 128. Raw Materials Key Suppliers Lists
• Table 129. Radioimmunotherapy Manufacturing Cost Structure
• Table 130. Radioimmunotherapy Downstream Customers
• Table 131. Radioimmunotherapy Distributors List
• Table 132. Research Programs/Design for This Report
• Table 133. Key Data Information from Secondary Sources
• Table 134. Key Data Information from Primary Sources

List of Figures

• Figure 1. Radioimmunotherapy Product Picture
• Figure 2. Global Radioimmunotherapy Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
• Figure 3. Global Radioimmunotherapy Sales Value (2019-2030) & (US$ Million)
• Figure 4. Radioimmunotherapy Report Years Considered
• Figure 5. Global Radioimmunotherapy Players Revenue Ranking (2023) & (US$ Million)
• Figure 6. The 5 Largest Companies in the World: Market Share by Radioimmunotherapy Revenue in 2023
• Figure 7. Ibritumomab Features
• Figure 8. Tositumomab Features
• Figure 9. Targeted Alpha Therapy Picture
• Figure 10. Global Radioimmunotherapy Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
• Figure 11. Global Radioimmunotherapy Sales Value Market Share by Type, 2023
• Figure 12. Global Radioimmunotherapy Sales Value Market Share by Type, 2030
• Figure 13. Prostate Cancer
• Figure 14. Product Picture of Non Hodgkin Lymphoma
• Figure 15. Global Radioimmunotherapy Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
• Figure 16. Global Radioimmunotherapy Sales Value Market Share by Application, 2023
• Figure 17. Global Radioimmunotherapy Sales Value Market Share by Application, 2030
• Figure 18. Global Radioimmunotherapy Sales Market Share in Value by Application (2025-2030)
• Figure 19. North America Radioimmunotherapy Sales Value (2019-2030) & (US$ Million)
• Figure 20. North America Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030
• Figure 21. Europe Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
• Figure 22. Europe Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030
• Figure 23. Asia Pacific Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
• Figure 24. Asia Pacific Radioimmunotherapy Sales Value by Region (%), 2023
• Figure 25. Asia Pacific Radioimmunotherapy Sales Value by Region (%), 2030
• Figure 26. South America Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
• Figure 27. South America Radioimmunotherapy Sales Value by Country (%), 2023
• Figure 28. South America Radioimmunotherapy Sales Value by Country (%), 2030
• Figure 29. Middle East & Africa Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
• Figure 30. Middle East & Africa Radioimmunotherapy Sales Value by Country (%), 2023
• Figure 31. Middle East & Africa Radioimmunotherapy Sales Value by Country (%), 2030
• Figure 32. Key Countries/Regions Radioimmunotherapy Sales Value (%), (2019-2030)
• Figure 33. North America Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
• Figure 34. North America Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
• Figure 35. North America Radioimmunotherapy Sales Value by Application (%), 2023 VS 2030
• Figure 36. Europe Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
• Figure 37. Europe Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
• Figure 38. Europe Radioimmunotherapy Sales Value by Application (%), 2023 VS 2030
• Figure 39. Asia Pacific Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
• Figure 40. Asia Pacific Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
• Figure 41. Asia Pacific Radioimmunotherapy Sales Value by Application (%), 2023 VS 2030
• Figure 42. South America Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
• Figure 43. South America Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
• Figure 44. South America Radioimmunotherapy Sales Value by Application (%), 2023 VS 2030
• Figure 45. Middle East and Africa Radioimmunotherapy Sales Value, (2019-2030) & (US$ Million)
• Figure 46. Middle East and Africa Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
• Figure 47. Middle East and Africa Radioimmunotherapy Sales Value by Application (%), 2023 VS 2030
• Figure 48. Bayer Revenue Growth Rate in Radioimmunotherapy Business (2019-2024)
• Figure 49. Novartis Revenue Growth Rate in Radioimmunotherapy Business (2019-2024)
• Figure 50. Lantheus Revenue Growth Rate in Radioimmunotherapy Business (2019-2024)
• Figure 51. Aurobindo Pharma Revenue Growth Rate in Radioimmunotherapy Business (2019-2024)
• Figure 52. Mundipharma Revenue Growth Rate in Radioimmunotherapy Business (2019-2024)
• Figure 53. China Isotope & Radiation Revenue Growth Rate in Radioimmunotherapy Business (2019-2024)
• Figure 54. Curium Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2019-2024)
• Figure 55. Radioimmunotherapy Industrial Chain
• Figure 56. Channels of Distribution
• Figure 57. Bottom-up and Top-down Approaches for This Report
• Figure 58. Data Triangulation
• Figure 59. Key Executives Interviewed

The global market for Radioimmunotherapy was estimated to be worth US$ 1865 million in 2023 and is forecast to a readjusted size of US$ 5408 million by 2030 with a CAGR of 14.63% during the forecast period 2024-2030.

North American market for Radioimmunotherapy was valued at $ 1100 million in 2023 and will reach $ 3274 million by 2030, at a CAGR of 14.13% during the forecast period of 2024 through 2030.

Asia-Pacific market for Radioimmunotherapy was valued at $ 171.72 million in 2023 and will reach $ 534.7 million by 2030, at a CAGR of 18.84% during the forecast period of 2024 through 2030.

Europe market for Radioimmunotherapy was valued at $ 574.41 million in 2023 and will reach $ 1581.23 million by 2030, at a CAGR of 14.48% during the forecast period of 2024 through 2030.

The global key companies of Radioimmunotherapy include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, etc. In 2023, the global five largest players hold a share approximately 99.45% in terms of revenue.

This report aims to provide a comprehensive presentation of the global market for Radioimmunotherapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Radioimmunotherapy by region & country, by Type, and by Application.

The Radioimmunotherapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radioimmunotherapy.

Market Segmentation

By Company

• Bayer
• Novartis
• Lantheus
• Aurobindo Pharma
• Mundipharma
• China Isotope & Radiation
• Curium Pharmaceuticals
• Gilead Sciences
• Clarity Pharmaceuticals
• Curasight
• Nordic Nanovector
• Philogen
• RadioMedix
• Telix Pharmaceuticals
• Orano Med
• Actinium Pharmaceuticals
• Y-mAbs Therapeutics
• Fusion Pharmaceuticals

Segment by Type

• Beta-emitting
• Targeted Alpha Therapy

Segment by Application

• Solid Tumor
• Non Hodgkin Lymphoma

By Region

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• Japan
• South Korea
• Southeast Asia
• India
• Other
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Rest of Europe
• South America
• Brazil
• Rest of South America
• Middle East & Africa
• Middle East
• Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Radioimmunotherapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Radioimmunotherapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Radioimmunotherapy in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Radioimmunotherapy Product Introduction
• 1.2 Global Radioimmunotherapy Market Size Forecast (2019-2030)
• 1.3 Radioimmunotherapy Market Trends & Drivers
  • 1.3.1 Radioimmunotherapy Industry Trends
  • 1.3.2 Radioimmunotherapy Market Drivers & Opportunity
  • 1.3.3 Radioimmunotherapy Market Challenges
  • 1.3.4 Radioimmunotherapy Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Radioimmunotherapy Players Revenue Ranking (2023)
• 2.2 Global Radioimmunotherapy Revenue by Company (2019-2024)
• 2.3 Key Companies Radioimmunotherapy Area Served and Headquarters
• 2.4 Key Companies Radioimmunotherapy Product Offered
• 2.5 Global Key Players of Radioimmunotherapy, Date of Enter into This Industry
• 2.6 Radioimmunotherapy Market Competitive Analysis
  • 2.6.1 Radioimmunotherapy Market Concentration Rate (2019-2024)
  • 2.6.2 Global 5 Largest Companies by Radioimmunotherapy Revenue in 2023
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioimmunotherapy as of 2023)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Beta-emitting
  • 3.1.2 Targeted Alpha Therapy
• 3.2 Global Radioimmunotherapy Sales Value by Type
  • 3.2.1 Global Radioimmunotherapy Sales Value by Type (2019 VS 2023 VS 2030)
  • 3.2.2 Global Radioimmunotherapy Sales Value, by Type (2019-2030)
  • 3.2.3 Global Radioimmunotherapy Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Solid Tumor
  • 4.1.2 Non Hodgkin Lymphoma
• 4.2 Global Radioimmunotherapy Sales Value by Application
  • 4.2.1 Global Radioimmunotherapy Sales Value by Application (2019 VS 2023 VS 2030)
  • 4.2.2 Global Radioimmunotherapy Sales Value, by Application (2019-2030)
  • 4.2.3 Global Radioimmunotherapy Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

• 5.1 Global Radioimmunotherapy Sales Value by Region
  • 5.1.1 Global Radioimmunotherapy Sales Value by Region: 2019 VS 2023 VS 2030
  • 5.1.2 Global Radioimmunotherapy Sales Value by Region (2019-2024)
  • 5.1.3 Global Radioimmunotherapy Sales Value by Region (2025-2030)
  • 5.1.4 Global Radioimmunotherapy Sales Value by Region (%), (2019-2030)
• 5.2 North America
  • 5.2.1 North America Radioimmunotherapy Sales Value, 2019-2030
  • 5.2.2 North America Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030
• 5.3 Europe
  • 5.3.1 Europe Radioimmunotherapy Sales Value, 2019-2030
  • 5.3.2 Europe Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Radioimmunotherapy Sales Value, 2019-2030
  • 5.4.2 Asia Pacific Radioimmunotherapy Sales Value by Region (%), 2023 VS 2030
• 5.5 South America
  • 5.5.1 South America Radioimmunotherapy Sales Value, 2019-2030
  • 5.5.2 South America Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Radioimmunotherapy Sales Value, 2019-2030
  • 5.6.2 Middle East & Africa Radioimmunotherapy Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Radioimmunotherapy Sales Value Growth Trends, 2019 VS 2023 VS 2030
• 6.2 Key Countries/Regions Radioimmunotherapy Sales Value, 2019-2030
• 6.3 North America
  • 6.3.1 North America Radioimmunotherapy Sales Value, 2019-2030
  • 6.3.2 North America Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
  • 6.3.3 North America Radioimmunotherapy Sales Value by Application, 2023 VS 2030
• 6.4 Europe
  • 6.4.1 Europe Radioimmunotherapy Sales Value, 2019-2030
  • 6.4.2 Europe Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
  • 6.4.3 Europe Radioimmunotherapy Sales Value by Application, 2023 VS 2030
• 6.5 Asia Pacific
  • 6.5.1 Asia Pacific Radioimmunotherapy Sales Value, 2019-2030
  • 6.5.2 Asia Pacific Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
  • 6.5.3 Asia Pacific Radioimmunotherapy Sales Value by Application, 2023 VS 2030
• 6.6 South America
  • 6.6.1 South America Radioimmunotherapy Sales Value, 2019-2030
  • 6.6.2 South America Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
  • 6.6.3 South America Radioimmunotherapy Sales Value by Application, 2023 VS 2030
• 6.7 Middle East and Africa
  • 6.7.1 Middle East and Africa Radioimmunotherapy Sales Value, 2019-2030
  • 6.7.2 Middle East and Africa Radioimmunotherapy Sales Value by Type (%), 2023 VS 2030
  • 6.7.3 Middle East and Africa Radioimmunotherapy Sales Value by Application, 2023 VS 2030

7 Company Profiles

• 7.1 Bayer
  • 7.1.1 Bayer Company Details
  • 7.1.2 Bayer Business Overview
  • 7.1.3 Bayer Radioimmunotherapy Products and Services
  • 7.1.4 Bayer Revenue in Radioimmunotherapy Business (2019-2024)
  • 7.1.5 Bayer Radioimmunotherapy SWOT Analysis
  • 7.1.6 Bayer Business Strategy
• 7.2 Novartis
  • 7.2.1 Novartis Company Details
  • 7.2.2 Novartis Business Overview
  • 7.2.3 Novartis Radioimmunotherapy Products and Services
  • 7.2.4 Novartis Revenue in Radioimmunotherapy Business (2019-2024)
  • 7.2.5 Novartis Radioimmunotherapy SWOT Analysis
  • 7.2.6 Novartis Business Strategy
• 7.3 Lantheus
  • 7.3.1 Lantheus Company Details
  • 7.3.2 Lantheus Business Overview
  • 7.3.3 Lantheus Radioimmunotherapy Products and Services
  • 7.3.4 Lantheus Revenue in Radioimmunotherapy Business (2019-2024)
  • 7.3.5 Lantheus Radioimmunotherapy SWOT Analysis
  • 7.3.6 Lantheus Business Strategy
• 7.4 Aurobindo Pharma
  • 7.4.1 Aurobindo Pharma Company Details
  • 7.4.2 Aurobindo Pharma Business Overview
  • 7.4.3 Aurobindo Pharma Radioimmunotherapy Products and Services
  • 7.4.4 Aurobindo Pharma Revenue in Radioimmunotherapy Business (2019-2024)
  • 7.4.5 Aurobindo Pharma Radioimmunotherapy SWOT Analysis
  • 7.4.6 Aurobindo Pharma Business Strategy
• 7.5 Mundipharma
  • 7.5.1 Mundipharma Company Details
  • 7.5.2 Mundipharma Business Overview
  • 7.5.3 Mundipharma Radioimmunotherapy Products and Services
  • 7.5.4 Mundipharma Revenue in Radioimmunotherapy Business (2019-2024)
  • 7.5.5 Mundipharma Business Strategy
• 7.6 China Isotope & Radiation
  • 7.6.1 China Isotope & Radiation Company Details
  • 7.6.2 China Isotope & Radiation Business Overview
  • 7.6.3 China Isotope & Radiation Radioimmunotherapy Products and Services
  • 7.6.4 China Isotope & Radiation Revenue in Radioimmunotherapy Business (2019-2024)
  • 7.6.5 China Isotope & Radiation Radioimmunotherapy SWOT Analysis
  • 7.6.6 China Isotope & Radiation Business Strategy
• 7.7 Curium Pharmaceuticals
  • 7.7.1 Curium Pharmaceuticals Company Details
  • 7.7.2 Curium Pharmaceuticals Business Overview
  • 7.7.3 Curium Pharmaceuticals Radioimmunotherapy Products and Services
  • 7.7.4 Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2019-2024)
  • 7.7.5 Curium Pharmaceuticals Radioimmunotherapy SWOT Analysis
  • 7.7.6 Curium Pharmaceuticals Business Strategy
• 7.8 Gilead Sciences
  • 7.8.1 Gilead Sciences Company Details
  • 7.8.2 Gilead Sciences Business Overview
  • 7.8.3 Gilead Sciences Radioimmunotherapy Products and Services
  • 7.8.4 Gilead Sciences Business Strategy
• 7.9 Clarity Pharmaceuticals
  • 7.9.1 Clarity Pharmaceuticals Company Details
  • 7.9.2 Clarity Pharmaceuticals Business Overview
  • 7.9.3 Clarity Pharmaceuticals Radioimmunotherapy Products and Services
  • 7.9.4 Clarity Pharmaceuticals Radioimmunotherapy SWOT Analysis
  • 7.9.5 Clarity Pharmaceuticals Business Strategy
• 7.10 Curasight
  • 7.10.1 Curasight Company Details
  • 7.10.2 Curasight Business Overview
  • 7.10.3 Curasight Radioimmunotherapy Products and Services
  • 7.10.4 Curasight Radioimmunotherapy SWOT Analysis
  • 7.10.5 Curasight Business Strategy
• 7.11 Nordic Nanovector
  • 7.11.1 Nordic Nanovector Company Details
  • 7.11.2 Nordic Nanovector Business Overview
  • 7.11.3 Nordic Nanovector Radioimmunotherapy Products and Services
  • 7.11.4 Nordic Nanovector Radioimmunotherapy SWOT Analysis
  • 7.11.5 Nordic Nanovector Business Strategy
• 7.12 Philogen
  • 7.12.1 Philogen Company Details
  • 7.12.2 Philogen Business Overview
  • 7.12.3 Philogen Radioimmunotherapy Products and Services
  • 7.12.4 Philogen Radioimmunotherapy SWOT Analysis
  • 7.12.5 Philogen Business Strategy
• 7.13 RadioMedix
  • 7.13.1 RadioMedix Company Details
  • 7.13.2 RadioMedix Business Overview
  • 7.13.3 RadioMedix Radioimmunotherapy Products and Services
  • 7.13.4 RadioMedix Business Strategy
• 7.14 Telix Pharmaceuticals
  • 7.14.1 Telix Pharmaceuticals Company Details
  • 7.14.2 Telix Pharmaceuticals Business Overview
  • 7.14.3 Telix Pharmaceuticals Radioimmunotherapy Products and Services
  • 7.14.4 Telix Pharmaceuticals Radioimmunotherapy SWOT Analysis
  • 7.14.5 Telix Pharmaceuticals Business Strategy
• 7.15 Orano Med
  • 7.15.1 Orano Med Company Details
  • 7.15.2 Orano Med Business Overview
  • 7.15.3 Orano Med Radioimmunotherapy Products and Services
  • 7.15.4 Orano Med Radioimmunotherapy SWOT Analysis
  • 7.15.5 Orano Med Business Strategy
• 7.16 Actinium Pharmaceuticals
  • 7.16.1 Actinium Pharmaceuticals Company Details
  • 7.16.2 Actinium Pharmaceuticals Business Overview
  • 7.16.3 Actinium Pharmaceuticals Radioimmunotherapy Products and Services
  • 7.16.4 Actinium Pharmaceuticals Radioimmunotherapy SWOT Analysis
  • 7.16.5 Actinium Pharmaceuticals Business Strategy
• 7.17 Y-mAbs Therapeutics
  • 7.17.1 Y-mAbs Therapeutics Company Details
  • 7.17.2 Y-mAbs Therapeutics Business Overview
  • 7.17.3 Y-mAbs Therapeutics Radioimmunotherapy Products and Services
  • 7.17.4 Y-mAbs Therapeutics Business Strategy
• 7.18 Fusion Pharmaceuticals
  • 7.18.1 Fusion Pharmaceuticals Company Details
  • 7.18.2 Fusion Pharmaceuticals Business Overview
  • 7.18.3 Fusion Pharmaceuticals Radioimmunotherapy Products and Services
  • 7.18.4 Fusion Pharmaceuticals Business Strategy

8 Industry Chain Analysis

• 8.1 Radioimmunotherapy Industrial Chain
• 8.2 Radioimmunotherapy Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Radioimmunotherapy Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Radioimmunotherapy Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
  • 10.1.2 Data Source
• 10.2 Author Details
• 10.3 Disclaimer